Would the choice of multiplex platform impact the management of the allergic patient? A first approach focusing on LTPs.
ALEX2
ISAC
LTP
clinical impact
comparison
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
06
07
2023
received:
31
01
2023
accepted:
21
08
2023
medline:
10
10
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
In the Mediterranean area, patients with LTP syndrome who are sensitized to multiple allergens are often tested for sIgE using multiplex platforms. The results obtained from different commercial platforms are not interchangeable, so it is important to compare and validate the platform selected for use. The objective of this study is to compare and validate the performance of the ImmunoCAP ISAC E112i and the macroarray ALEX2 in our daily practice. From August 2021 to March 2022, we tested 20 random serum samples from polysensitized patients using the ALEX2 test (MADx) and ImmunoCAP tIgE and ISAC E112i (Thermo Fisher Scientific). We compared the total IgE (tIgE) and sIgE levels for shared allergens. The heatmap generally showed more intense results for ISAC. The overall correlation was good, but some exceptions were noted. The main discrepancies were found for Ole e 7, which was positive for 11 patients in ISAC but negative for all patients in ALEX2, and for nut LTPs, for which ISAC showed a threefold higher detection rate for Ara h 9 and a fivefold higher detection rate for Cor a 8 and Jug r 3 compared to ALEX2. The regression model showed no interchangeability of tIgE results. Despite our small sample size and the complexity of comparing a quantitative and a semi-quantitative platform, our results suggest that patient diagnosis and management can be influenced by the platform used. Therefore, our findings must be taken into consideration when choosing a platform to use for some profiles of LTP-polysensitized patients, even though more data is needed.
Sections du résumé
BACKGROUND
BACKGROUND
In the Mediterranean area, patients with LTP syndrome who are sensitized to multiple allergens are often tested for sIgE using multiplex platforms. The results obtained from different commercial platforms are not interchangeable, so it is important to compare and validate the platform selected for use. The objective of this study is to compare and validate the performance of the ImmunoCAP ISAC E112i and the macroarray ALEX2 in our daily practice.
METHODS
METHODS
From August 2021 to March 2022, we tested 20 random serum samples from polysensitized patients using the ALEX2 test (MADx) and ImmunoCAP tIgE and ISAC E112i (Thermo Fisher Scientific). We compared the total IgE (tIgE) and sIgE levels for shared allergens.
RESULTS
RESULTS
The heatmap generally showed more intense results for ISAC. The overall correlation was good, but some exceptions were noted. The main discrepancies were found for Ole e 7, which was positive for 11 patients in ISAC but negative for all patients in ALEX2, and for nut LTPs, for which ISAC showed a threefold higher detection rate for Ara h 9 and a fivefold higher detection rate for Cor a 8 and Jug r 3 compared to ALEX2. The regression model showed no interchangeability of tIgE results.
CONCLUSIONS
CONCLUSIONS
Despite our small sample size and the complexity of comparing a quantitative and a semi-quantitative platform, our results suggest that patient diagnosis and management can be influenced by the platform used. Therefore, our findings must be taken into consideration when choosing a platform to use for some profiles of LTP-polysensitized patients, even though more data is needed.
Identifiants
pubmed: 37638561
doi: 10.1002/jcla.24960
pmc: PMC10561593
doi:
Substances chimiques
Immunoglobulin E
37341-29-0
Allergens
0
Arabinonucleosides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24960Subventions
Organisme : Thermo Fisher Scientific
Informations de copyright
© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Curr Allergy Asthma Rep. 2018 Sep 11;18(11):56
pubmed: 30206718
Allergy. 2022 Oct;77(10):3028-3040
pubmed: 35485989
Clin Chim Acta. 2019 Jun;493:73-78
pubmed: 30822401
Pediatr Allergy Immunol. 2016 May;27 Suppl 23:1-250
pubmed: 27288833
Ann Allergy Asthma Immunol. 2022 Mar;128(3):283-290.e4
pubmed: 34863952
Allergy. 2021 Dec;76(12):3642-3658
pubmed: 34057744
J Clin Lab Anal. 2023 Aug;37(15-16):e24960
pubmed: 37638561
Allergy. 2015 Aug;70(8):933-43
pubmed: 25903791
Clin Exp Allergy. 2021 Dec;51(12):1603-1612
pubmed: 34523179